Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,740 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroendocrine Cancer Clear all
Completed Phase 2 Interventional Results available

Lithium for Low-Grade Neuroendocrine Tumors

NCT00501540
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Lithium Carbonate
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 21, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

NCT01619774
View directory record Official record
Conditions
Melanoma
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 21, 2026, 6:53 PM EDT
Withdrawn Not applicable Interventional

Evaluating the Pre-Positioning Frame for Robotic Acoustic Neuroma Removal Surgery

NCT03057678
View directory record Official record
Conditions
Acoustic Neuroma
Interventions
Testing of Pre-Positioning Frame
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated No phase listed Observational

Sample Collection From Melanoma Patients

NCT00507325
View directory record Official record
Conditions
Melanoma
Interventions
Blood Sample, Tumor Sample
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 21, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

NCT00328861
View directory record Official record
Conditions
Metastatic Melanoma, Metastatic Kidney Cancer
Interventions
Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

NCT01236573
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Fludarabine, Cyclophosphamide, IL-12 transduced TIL
Drug · Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 66 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

NCT00466856
View directory record Official record
Conditions
Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
Interventions
octreotide acetate, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 1 Interventional

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
View directory record Official record
Conditions
Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
Interventions
ASN003 ascending doses, ASN003 MTD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

IMCgp100-401 Rollover Study

NCT02889861
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IMCgp100
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and EDP1503 in Advanced Melanoma

NCT03595683
View directory record Official record
Conditions
Melanoma (Skin), Melanoma
Interventions
Pembrolizumab, EDP1503
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 21, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

NCT01844505
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
46
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 21, 2026, 6:53 PM EDT
Completed No phase listed Observational

Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma

NCT00745862
View directory record Official record
Conditions
Melanoma
Interventions
questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Metronomic Therapy in Patients With Metastatic Melanoma

NCT01542255
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
vinblastine, Cyclophosphamide, dacarbazine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 21, 2026, 6:53 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

NCT06548789
View directory record Official record
Conditions
Melanoma
Interventions
Prebiotic Xnack Packouts
Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 1 Interventional

Safety Study of MGD009 in B7-H3-expressing Tumors

NCT02628535
View directory record Official record
Conditions
Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
Interventions
MGD009
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Not applicable Interventional Results available

Reinforced Staple Line on Leak Rate in Distal Pancreatectomy

NCT01359410
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Mesh reinforced staple line (SEAMGUARD), Stapled without mesh reinforcement (PER-STRIPS DRY)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

NCT03747484
View directory record Official record
Conditions
Other Skin
Interventions
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab, Interferon Gamma-1b
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550
View directory record Official record
Conditions
Melanoma, Colonic Neoplasms, Breast Neoplasms
Interventions
PD-0325901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 21, 2026, 6:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 21, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Irofulven in Treating Patients With Stage IV Melanoma

NCT00005968
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
irofulven
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
5
States / cities
Santa Monica, California • Denver, Colorado • Park Ridge, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 21, 2026, 6:53 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590
View directory record Official record
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional

ITIL-168 in Advanced Melanoma

NCT05050006
View directory record Official record
Conditions
Advanced Cutaneous Melanoma
Interventions
ITIL-168
Biological
Lead sponsor
Instil Bio
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 21, 2026, 6:53 PM EDT